INTERVENTIONALUNKNOWNNCT04726475
Impact of Cannabidiol-Rich Hemp Extract Oil on Reconsolidation Disruption of Naturalistic Interoceptive Aversive Memory in Humans
The purpose of this study is to test whether cannabidiol (CBD) rich hemp extract oil can interfere with the reconsolidation (storage) of pathological fear memory in humans.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.gov↗last source update 2022-01-19
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASE1, PHASE2
- Enrollment
- 96 (ESTIMATED)
- Start date
- 2022-01
- Sponsor
- University of Texas at Austin
- Design
- RANDOMIZED · PARALLEL · TREATMENT
- Locations
- 1
- Results record
- Not present in registry snapshot
Preclinical experiments demonstrate that isolated cannabidiol (CBD), the non-psychotomimetic constituent of the Cannabis sativa plant, disrupts reconsolidation of aversive memories conditioned in the laboratory when administered within the memory reconsolidation window (\< 6 hrs. post-retrieval) by indirectly activating cannabinoid type-1 (CB1) receptors in the dorsal anterior cingulate cortex (dACC). Furthermore, background material (e.g., terpenoids) naturally present in the cannabis plant may also disrupt aversive memory reconsolidation both alone and in concert with CBD. Based on these preclinical findings, we aim to test whether administration of 300mg CBD-rich hemp extract oil following fear reactivation of an aversive interoceptive threat memory can disrupt reconsolidation of naturalistic aversive memories in humans. More specifically, naturalistic interoceptive aversive memories, a form of transdiagnostic fear memory that contributes to the pathogenesis of fear-related disorders such as panic disorder, posttraumatic stress disorder (PTSD), and illness anxiety disorder. For this proof-of-concept double-blind trial, volunteers (n=96) reporting elevated fears of somatic sensations will be stratified on biological sex and baseline levels of interoceptive fear and randomized to one of three intervention arms: (a). CBD-rich oil administered within the reconsolidation window, (b). Placebo oil administered within the reconsolidation window, or (c). CBD-rich oil administered outside of the reconsolidation window. Change in emotional reactivity to a 35% CO2 challenge from baseline to two-week follow-up will serve as our primary outcome. Study findings may contribute towards the development of a novel ultra-brief transdiagnostic intervention guided by reconsolidation theory for individuals prone to fear-related psychiatric disorders.
Anxiety and Fear
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Conditions
No published condition report matched.
Cannabinoids and active compounds
Medicines
No exact medicine-name link was found.
Research network
Researchers and organizations
Interventions
What was registered
BEHAVIORALInteroceptive Aversive Memory Reactivation
In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
DIETARY SUPPLEMENTCannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil
300mg CBD-rich hemp-derived formulation in MCT coconut oil.
DIETARY SUPPLEMENTPlacebo Oil
3ml oral dose of MCT coconut oil.
Eligibility
Population and criteria
- Sex
- ALL
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Healthy volunteers
- Not accepted
Inclusion criteria
- include: 1. Ages 18-65 2. Fluent in English 3. Willingness to refrain from all non-study cannabis use during the study period.
Exclusion criteria
- include: 1. Insufficient phobicity (\<50 on CO2 challenge); 2. Presence of significant suicidality; 3. History of psychosis; 4. Currently receiving exposure-based treatment; 5. Current substance use disorder; 6. Unstable psychiatric medication for a psychological condition; 7. Medical conditions contraindicating CO2 inhalation (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke); 8. Any medical problems (e.g., liver or renal abnormalities) or medication use that would preclude ingesting CBD oil, including but not limited to currently taking blood thinners (e.g., Warfarin and some anti-epileptic medications); 9. History of an adverse reaction to CBD oil or other CBD products, 10. Coconut allergy (coconut oil is the carrier oil for CBD-rich extract) (l) Regular cannabis use
primary outcomes
primary measures
CO2 Emotional Reactivity
Time frame: Two-week follow-up
Self-reported peak-distress (range: 0-100), defined as the highest level of distress experienced at any point during the 35% CO2 challenge completed at the two-week follow-up assessment, adjusting for baseline rating (immediately after the 35% CO2 challenge, but before receiving either immediate CBD/placebo or delayed CBD).
secondary outcomes
secondary measures
CO2 Emotional Distress Recovery Trajectory
Time frame: Two-week follow-up
Participants will be asked to rate their current distress level (range: 0-100) every minute for five consecutive minutes after the CO2 inhalation (recovery phase). Change in CO2 emotional distress recovery trajectory from baseline to the two-week follow will serve as a secondary continuous index of emotional reactivity to somatic cues.
Short Scale Anxiety Sensitivity Index (SASSI)
Time frame: Two-week
The 5-item SSASI is a self-report instrument designed to measure the transdiagnostic construct of anxiety sensitivity, defined as a fear of anxiety and arousal-related sensations. Change on the SSASI from baseline to the two-week follow-up will serve as a secondary outcome measure.
Publications
Locally readable linked articles
background referenceFrontiers in Behavioral Neuroscience · Free full text Snapshot provenance
- Snapshot
- e25daf24-7cb1-4b38-9159-f59f8ba7c7cc
- Retrieved
- 11/09/2026, 14:54:04
- SHA-256
- a94ab0ec3714ae5f1b374418144d9017c2c10b9804304985099b36d689d077ae